3D cell culture systems modeling tumor growth determinants in cancer target discovery

Advanced Drug Delivery Reviews

Volumn 69-70, Issue , 2014, Pages 29-41

  Thoma, Claudio R ^a   Zimmermann, Miriam ^a   Agarkova, Irina ^b   Kelm, Jens M ^b   Krek, Wilhelm ^a  

^a ETH ZURICH   (Switzerland)

^b InSphero AG   (Switzerland)

Author keywords

3D cell culture; Cancer cell signaling; Molecular cancer targets; Multicellular tumor spheroid (MCTS); Screening technology; Tumor microenvironment

Indexed keywords

CELL CULTURE; CELL SIGNALING; CELLS; CROSSTALK; DIAGNOSIS; DISEASES; SIGNALING; TOOLS; TUMORS;

3-D CELL CULTURE; INTERCELLULAR SIGNALING; MICROENVIRONMENTS; MULTICELLULAR TUMOR SPHEROIDS; SCREENING TECHNOLOGY; TECHNOLOGICAL ASPECTS; TUMOR DEVELOPMENT; TUMOR MICROENVIRONMENT;

THREE DIMENSIONAL;

ANTINEOPLASTIC AGENT; DRUG METABOLITE; GROWTH FACTOR;

BIOSENSOR; BIOTECHNOLOGY; CANCER CELL; CANCER GROWTH; CANCER MODEL; CANCER RESISTANCE; CELL CULTURE; CELL HETEROGENEITY; CELL TYPE; COCULTURE; CULTURE TECHNIQUE; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MOLECULAR MODEL; MULTICELLULAR SPHEROID; NONHUMAN; ONLINE ANALYSIS; PH; PHENOTYPE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPHEROID CELL; TARGET CELL DESTRUCTION; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; VALIDATION STUDY; ANIMAL; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; DRUG DISCOVERY; HUMANS; NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR MICROENVIRONMENT;

EID: 84899945356     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.03.001     Document Type: Review

References (154)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Bates S.E., Amiri-Kordestani L., Giaccone G. Drug development: portals of discovery. Clin. Cancer Res. 2012, 18:23-32.
3. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501:346-354.
4. Watson I.R., Takahashi K., Futreal P.A., Chin L. Emerging patterns of somatic mutations in cancer. Nat. Rev. Genet. 2013, 14:703-718.
5. De Sousa E.M.F., Vermeulen L., Fessler E., Medema J.P. Cancer heterogeneity-a multifaceted view. EMBO Rep. 2013, 14:686-695.
6. Albini A., Sporn M.B. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 2007, 7:139-147.
7. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 2010, 18:884-901.
8. Polyak K., Haviv I., Campbell I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009, 25:30-38.
9. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
10. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
11. Becker J.C., Andersen M.H., Schrama D., Thor Straten P. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol. Immunother. 2013, 62:1137-1148.
12. Paraiso K.H., Smalley K.S. Fibroblast-mediated drug resistance in cancer. Biochem. Pharmacol. 2013, 85:1033-1041.
13. Ryan G.B., Cliff W.J., Gabbiani G., Irle C., Statkov P.R., Majno G. Myofibroblasts in an avascular fibrous tissue. Lab. Invest. 1973, 29:197-206.
14. Barsky S.H., Green W.R., Grotendorst G.R., Liotta L.A. Desmoplastic breast carcinoma as a source of human myofibroblasts. Am. J. Pathol. 1984, 115:329-333.
15. Pickup M., Novitskiy S., Moses H.L. The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer 2013, 13:788-799.
16. Siegel P.M., Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 2003, 3:807-821.
17. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., Washington M.K., Neilson E.G., Moses H.L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851.
18. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., Richardson A., Weinberg R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4966-4971.
19. Bridle K.R., Crawford D.H., Powell L.W., Ramm G.A. Role of myofibroblasts in tumour encapsulation of hepatocellular carcinoma in haemochromatosis. Liver 2001, 21:96-104.
20. Shimasaki N., Kuroda N., Guo L., Jin Y., Miyazaki E., Hayashi Y., Toi M., Hiroi M., Enzan H., Shuin T. The participation of myofibroblasts in the capsular formation of human conventional and chromophobe renal cell carcinomas. Histol. Histopathol. 2005, 20:67-73.
21. Pavlides S., Whitaker-Menezes D., Castello-Cros R., Flomenberg N., Witkiewicz A.K., Frank P.G., Casimiro M.C., Wang C., Fortina P., Addya S., Pestell R.G., Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001.
22. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., Cooper Z.A., Chapman P.B., Solit D.B., Ribas A., Lo R.S., Flaherty K.T., Ogino S., Wargo J.A., Golub T.R. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
23. Chaturvedi P., Gilkes D.M., Wong C.C., Luo W., Zhang H., Wei H., Takano N., Schito L., Levchenko A., Semenza G.L. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J. Clin. Invest. 2013, 123:189-205.
24. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14:1014-1022.
25. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
26. Brem S., Brem H., Folkman J., Finkelstein D., Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 1976, 36:2807-2812.
27. Raica M., Cimpean A.M., Ribatti D. Angiogenesis in pre-malignant conditions. Eur. J. Cancer 2009, 45:1924-1934.
28. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012, 21:297-308.
29. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
30. Wu M., Frieboes H.B., McDougall S.R., Chaplain M.A., Cristini V., Lowengrub J. The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J. Theor. Biol. 2013, 320:131-151.
31. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6:583-592.
32. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
33. Gladwin M.T., Lancaster J.R., Freeman B.A., Schechter A.N. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat. Med. 2003, 9:496-500.
34. Burke A.J., Sullivan F.J., Giles F.J., Glynn S.A. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013, 34:503-512.
35. Wouters B.G., Brown J.M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res. 1997, 147:541-550.
36. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3:177-182.
37. Yasui H., Matsumoto S., Devasahayam N., Munasinghe J.P., Choudhuri R., Saito K., Subramanian S., Mitchell J.B., Krishna M.C. Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res. 2010, 70:6427-6436.
38. Dewhirst M.W., Cao Y., Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 2008, 8:425-437.
39. Durand R.E., LePard N.E. Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol. 1995, 34:317-323.
40. Cardenas-Navia L.I., Mace D., Richardson R.A., Wilson D.F., Shan S., Dewhirst M.W. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res. 2008, 68:5812-5819.
41. Kimura H., Braun R.D., Ong E.T., Hsu R., Secomb T.W., Papahadjopoulos D., Hong K., Dewhirst M.W. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 1996, 56:5522-5528.
42. 2 sensing and cancer. Nat. Rev. Cancer 2008, 8:865-873.
43. Yang Y., Sun M., Wang L., Jiao B. HIFs, angiogenesis, and cancer. J. Cell. Biochem. 2013, 114:967-974.
44. 2 availability on human cancer. Nat. Rev. Cancer 2008, 8:967-975.
45. Mole D.R., Blancher C., Copley R.R., Pollard P.J., Gleadle J.M., Ragoussis J., Ratcliffe P.J. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 2009, 284:16767-16775.
46. Xia X., Lemieux M.E., Li W., Carroll J.S., Brown M., Liu X.S., Kung A.L. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4260-4265.
47. Goldberg M.A., Dunning S.P., Bunn H.F. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988, 242:1412-1415.
48. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
49. Kourembanas S., Hannan R.L., Faller D.V. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J. Clin. Invest. 1990, 86:670-674.
50. Hitchon C., Wong K., Ma G., Reed J., Lyttle D., El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 2002, 46:2587-2597.
51. Ingle J.N. Pharmacogenomics of endocrine therapy in breast cancer. J. Hum. Genet. 2013, 58:306-312.
52. Rove K.O., Debruyne F.M., Djavan B., Gomella L.G., Koul H.K., Lucia M.S., Petrylak D.P., Shore N.D., Stone N.N., Crawford E.D. Role of testosterone in managing advanced prostate cancer. Urology 2012, 80:754-762.
53. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
54. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., van der Mey A., Taschner P.E., Rubinstein W.S., Myers E.N., Richard C.W., Cornelisse C.J., Devilee P., Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-851.
55. Flier J.S., Mueckler M.M., Usher P., Lodish H.F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987, 235:1492-1495.
56. Li B., Simon M.C. Molecular pathways: targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin. Cancer Res. 2013, 19:5835-5841.
57. Osthus R.C., Shim H., Kim S., Li Q., Reddy R., Mukherjee M., Xu Y., Wonsey D., Lee L.A., Dang C.V. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 2000, 275:21797-21800.
58. Ebert B.L., Firth J.D., Ratcliffe P.J. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J. Biol. Chem. 1995, 270:29083-29089.
59. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
60. Ivanov S.V., Kuzmin I., Wei M.H., Pack S., Geil L., Johnson B.E., Stanbridge E.J., Lerman M.I. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:12596-12601.
61. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
62. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., De Saedeleer C.J., Kennedy K.M., Diepart C., Jordan B.F., Kelley M.J., Gallez B., Wahl M.L., Feron O., Dewhirst M.W. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 2008, 118:3930-3942.
63. Curry J.M., Tuluc M., Whitaker-Menezes D., Ames J.A., Anantharaman A., Butera A., Leiby B., Cognetti D.M., Sotgia F., Lisanti M.P., Martinez-Outschoorn U.E. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle 2013, 12:1371-1384.
64. Pinheiro C., Longatto-Filho A., Azevedo-Silva J., Casal M., Schmitt F.C., Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J. Bioenerg. Biomembr. 2012, 44:127-139.
65. Vander Heiden M.G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 2011, 10:671-684.
66. Parks S.K., Chiche J., Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 2013, 13:611-623.
67. Geiger T.R., Peeper D.S. Metastasis mechanisms. Biochim. Biophys. Acta 2009, 1796:293-308.
68. Hart I.R. New evidence for tumour embolism as a mode of metastasis. J. Pathol. 2009, 219:275-276.
69. Mego M., Mani S.A., Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat. Rev. Clin. Oncol. 2010, 7:693-701.
70. Hunter K.W., Crawford N.P., Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008, 10(Suppl. 1):S2.
71. Buhmeida A., Pyrhonen S., Laato M., Collan Y. Prognostic factors in prostate cancer. Diagn. Pathol. 2006, 1:4.
72. Heinemann V., Reni M., Ychou M., Richel D.J., Macarulla T., Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat. Rev. 2014, 40:118-128.
73. Jiang B., Mason J., Jewett A., Liu M.L., Chen W., Qian J., Ding Y., Ding S., Ni M., Zhang X., Man Y.G. Tumor-infiltrating immune cells: triggers for tumor capsule disruption and tumor progression?. Int. J. Med. Sci. 2013, 10:475-497.
74. Keely P.J. Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. J. Mammary Gland Biol. Neoplasia 2011, 16:205-219.
75. Conklin M.W., Eickhoff J.C., Riching K.M., Pehlke C.A., Eliceiri K.W., Provenzano P.P., Friedl A., Keely P.J. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am. J. Pathol. 2011, 178:1221-1232.
76. Semenza G.L. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 2013, 32:4057-4063.
77. Moserle L., Casanovas O. Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. J. Intern. Med. 2013, 273:128-137.
78. Lubkin S.R., Jackson T. Multiphase mechanics of capsule formation in tumors. J. Biomech. Eng. 2002, 124:237-243.
79. Estrella V., Chen T., Lloyd M., Wojtkowiak J., Cornnell H.H., Ibrahim-Hashim A., Bailey K., Balagurunathan Y., Rothberg J.M., Sloane B.F., Johnson J., Gatenby R.A., Gillies R.J. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013, 73:1524-1535.
80. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoue F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
81. Azimi F., Scolyer R.A., Rumcheva P., Moncrieff M., Murali R., McCarthy S.W., Saw R.P., Thompson J.F. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J. Clin. Oncol. 2012, 30:2678-2683.
82. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
83. Borovski T., De Sousa E.M.F., Vermeulen L., Medema J.P. Cancer stem cell niche: the place to be. Cancer Res. 2011, 71:634-639.
84. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., Gilbertson R.J. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
85. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 1953, 26:638-648.
86. Meijer T.W., Kaanders J.H., Span P.N., Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin. Cancer Res. 2012, 18:5585-5594.
87. Song X., Liu X., Chi W., Liu Y., Wei L., Wang X., Yu J. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother. Pharmacol. 2006, 58:776-784.
88. Shannon A.M., Bouchier-Hayes D.J., Condron C.M., Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 2003, 29:297-307.
89. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
90. Pickl M., Ries C.H. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009, 28:461-468.
91. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
92. Zimmermann M., Box C., Eccles S.A. Two-dimensional vs. three-dimensional in vitro tumor migration and invasion assays. Methods Mol. Biol. 2013, 986:227-252.
93. Krausz E., de Hoogt R., Gustin E., Cornelissen F., Grand-Perret T., Janssen L., Vloemans N., Wuyts D., Frans S., Axel A., Peeters P.J., Hall B., Cik M. Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening. J. Biomol. Screen. 2013, 18:54-66.
94. Thoma C.R., Stroebel S., Rosch N., Calpe B., Krek W., Kelm J.M. A high-throughput-compatible 3D microtissue co-culture system for phenotypic RNAi screening applications. J. Biomol. Screen. 2013, 18:1330-1337.
95. Vinci M., Gowan S., Boxall F., Patterson L., Zimmermann M., Court W., Lomas C., Mendiola M., Hardisson D., Eccles S.A. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012, 10:29.
96. Leslie K., Gao S.P., Berishaj M., Podsypanina K., Ho H., Ivashkiv L., Bromberg J. Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res. 2010, 12:R80.
97. Wang Y., Niu X.L., Qu Y., Wu J., Zhu Y.Q., Sun W.J., Li L.Z. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010, 295:110-123.
98. Pu Y.S., Hour T.C., Chuang S.E., Cheng A.L., Lai M.K., Kuo M.L. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 2004, 60:120-129.
99. Greiner A.M., Richter B., Bastmeyer M. Micro-engineered 3D scaffolds for cell culture studies. Macromol. Biosci. 2012, 12:1301-1314.
100. Hoshiba T., Lu H., Kawazoe N., Chen G. Decellularized matrices for tissue engineering. Expert. Opin. Biol. Ther. 2010, 10:1717-1728.
101. Ott H.C., Matthiesen T.S., Goh S.K., Black L.D., Kren S.M., Netoff T.I., Taylor D.A. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat. Med. 2008, 14:213-221.
102. Uygun B.E., Soto-Gutierrez A., Yagi H., Izamis M.L., Guzzardi M.A., Shulman C., Milwid J., Kobayashi N., Tilles A., Berthiaume F., Hertl M., Nahmias Y., Yarmush M.L., Uygun K. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat. Med. 2010, 16:814-820.
103. Lu H., Hoshiba T., Kawazoe N., Koda I., Song M., Chen G. Cultured cell-derived extracellular matrix scaffolds for tissue engineering. Biomaterials 2011, 32:9658-9666.
104. Narayanan K., Leck K.J., Gao S., Wan A.C. Three-dimensional reconstituted extracellular matrix scaffolds for tissue engineering. Biomaterials 2009, 30:4309-4317.
105. Kleinman H.K., McGarvey M.L., Hassell J.R., Star V.L., Cannon F.B., Laurie G.W., Martin G.R. Basement membrane complexes with biological activity. Biochemistry 1986, 25:312-318.
106. Szot C.S., Buchanan C.F., Freeman J.W., Rylander M.N. 3D in vitro bioengineered tumors based on collagen I hydrogels. Biomaterials 2011, 32:7905-7912.
107. Tibbitt M.W., Anseth K.S. Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol. Bioeng. 2009, 103:655-663.
108. Yip D., Cho C.H. A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem. Biophys. Res. Commun. 2013, 433:327-332.
109. Fong E.L., Lamhamedi-Cherradi S.E., Burdett E., Ramamoorthy V., Lazar A.J., Kasper F.K., Farach-Carson M.C., Vishwamitra D., Demicco E.G., Menegaz B.A., Amin H.M., Mikos A.G., Ludwig J.A. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:6500-6505.
110. Fu Y., Xu K., Zheng X., Giacomin A.J., Mix A.W., Kao W.J. 3D cell entrapment in crosslinked thiolated gelatin-poly(ethylene glycol) diacrylate hydrogels. Biomaterials 2012, 33:48-58.
111. Napolitano A.P., Dean D.M., Man A.J., Youssef J., Ho D.N., Rago A.P., Lech M.P., Morgan J.R. Scaffold-free three-dimensional cell culture utilizing micromolded nonadhesive hydrogels. Biotechniques 2007, 494:496-500.
112. Zhang M., Boughton P., Rose B., Lee C.S., Hong A.M. The use of porous scaffold as a tumor model. Int. J. Biomater. 2013, 2013:396056.
113. Chandler E.M., Berglund C.M., Lee J.S., Polacheck W.J., Gleghorn J.P., Kirby B.J., Fischbach C. Stiffness of photocrosslinked RGD-alginate gels regulates adipose progenitor cell behavior. Biotechnol. Bioeng. 2011, 108:1683-1692.
114. Agudelo-Garcia P.A., De Jesus J.K., Williams S.P., Nowicki M.O., Chiocca E.A., Liyanarachchi S., Li P.K., Lannutti J.J., Johnson J.K., Lawler S.E., Viapiano M.S. Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. Neoplasia 2011, 13:831-840.
115. DeForest C.A., Polizzotti B.D., Anseth K.S. Sequential click reactions for synthesizing and patterning three-dimensional cell microenvironments. Nat. Mater. 2009, 8:659-664.
116. Dash A., Blackman B.R., Wamhoff B.R. Organotypic systems in drug metabolism and toxicity: challenges and opportunities. Expert Opin. Drug Metab. Toxicol. 2012, 8:999-1014.
117. Leclerc E., Corlu A., Griscom L., Baudoin R., Legallais C. Guidance of liver and kidney organotypic cultures inside rectangular silicone microchannels. Biomaterials 2006, 27:4109-4119.
118. Shami S.G., Aghajanian J.D., Sanders R.L. Organotypic culture of fetal lung type II alveolar epithelial cells: applications to pulmonary toxicology. Environ. Health Perspect. 1984, 56:87-94.
119. Vickers A.E., Fisher R.L. Organ slices for the evaluation of human drug toxicity. Chem. Biol. Interact. 2004, 150:87-96.
120. Sasai Y. Next-generation regenerative medicine: organogenesis from stem cells in 3D culture. Cell Stem Cell 2013, 12:520-530.
121. Achilli T.M., Meyer J., Morgan J.R. Advances in the formation, use and understanding of multi-cellular spheroids. Expert. Opin. Biol. Ther. 2012, 12:1347-1360.
122. Huh D., Hamilton G.A., Ingber D.E. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011, 21:745-754.
123. Kelm J.M., Djonov V., Ittner L.M., Fluri D., Born W., Hoerstrup S.P., Fussenegger M. Design of custom-shaped vascularized tissues using microtissue spheroids as minimal building units. Tissue Eng. 2006, 12:2151-2160.
124. Mueller-Klieser W. Method for the determination of oxygen consumption rates and diffusion coefficients in multicellular spheroids. Biophys. J. 1984, 46:343-348.
125. Freyer J.P., Sutherland R.M. Regulation of growth saturation and development of necrosis in EMT6/Ro multicellular spheroids by the glucose and oxygen supply. Cancer Res. 1986, 46:3504-3512.
126. Mueller-Klieser W., Freyer J.P., Sutherland R.M. Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids. Br. J. Cancer 1986, 53:345-353.
127. Khaitan D., Chandna S., Arya M.B., Dwarakanath B.S. Establishment and characterization of multicellular spheroids from a human glioma cell line; implications for tumor therapy. J. Transl. Med. 2006, 4:12.
128. Khaitan D., Dwarakanath B.S. Multicellular spheroids as an in vitro model in experimental oncology: applications in translational medicine. Expert Opin. Drug Discov. 2006, 1:663-675.
129. Zhou Y., Arai T., Horiguchi Y., Ino K., Matsue T., Shiku H. Multiparameter analyses of three-dimensionally cultured tumor spheroids based on respiratory activity and comprehensive gene expression profiles. Anal. Biochem. 2013, 439:187-193.
130. Ghosh S., Spagnoli G.C., Martin I., Ploegert S., Demougin P., Heberer M., Reschner A. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J. Cell. Physiol. 2005, 204:522-531.
131. Fischbach C., Kong H.J., Hsiong S.X., Evangelista M.B., Yuen W., Mooney D.J. Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:399-404.
132. Marushima H., Shibata S., Asakura T., Matsuura T., Maehashi H., Ishii Y., Eda H., Aoki K., Iida Y., Morikawa T., Ohkawa K. Three-dimensional culture promotes reconstitution of the tumor-specific hypoxic microenvironment under TGFbeta stimulation. Int. J. Oncol. 2011, 39:1327-1336.
133. Enzerink A., Salmenpera P., Kankuri E., Vaheri A. Clustering of fibroblasts induces proinflammatory chemokine secretion promoting leukocyte migration. Mol. Immunol. 2009, 46:1787-1795.
134. Klapperich C.M., Bertozzi C.R. Global gene expression of cells attached to a tissue engineering scaffold. Biomaterials 2004, 25:5631-5641.
135. Eckes B., Hunzelmann N., Ziegler-Heitbrock H.W., Urbanski A., Luger T., Krieg T., Mauch C. Interleukin-6 expression by fibroblasts grown in three-dimensional gel cultures. FEBS Lett. 1992, 298:229-232.
136. Clark A.K., Taubenberger A.V., Taylor R.A., Niranjan B., Chea Z.Y., Zotenko E., Sieh S., Pedersen J.S., Norden S., Frydenberg M., Grummet J.P., Pook D.W., Stirzaker C., Clark S.J., Lawrence M.G., Ellem S.J., Hutmacher D.W., Risbridger G.P. A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials 2013, 34:4777-4785.
137. Hama H., Kurokawa H., Kawano H., Ando R., Shimogori T., Noda H., Fukami K., Sakaue-Sawano A., Miyawaki A. Scale: a chemical approach for fluorescence imaging and reconstruction of transparent mouse brain. Nat. Neurosci. 2011, 14:1481-1488.
138. de Barros A.P., Takiya C.M., Garzoni L.R., Leal-Ferreira M.L., Dutra H.S., Chiarini L.B., Meirelles M.N., Borojevic R., Rossi M.I. Osteoblasts and bone marrow mesenchymal stromal cells control hematopoietic stem cell migration and proliferation in 3D in vitro model. PLoS One 2010, 5:e9093.
139. Ong S.M., Zhao Z., Arooz T., Zhao D., Zhang S., Du T., Wasser M., van Noort D., Yu H. Engineering a scaffold-free 3D tumor model for in vitro drug penetration studies. Biomaterials 2010, 31:1180-1190.
140. Asthana A., Kisaalita W.S. Microtissue size and hypoxia in HTS with 3D cultures. Drug Discov. Today 2012, 17:810-817.
141. Spivak-Kroizman T.R., Hostetter G., Posner R., Aziz M., Hu C., Demeure M.J., Von Hoff D., Hingorani S.R., Palculict T.B., Izzo J., Kiriakova G.M., Abdelmelek M., Bartholomeusz G., James B.P., Powis G. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res. 2013, 73:3235-3247.
142. Skiles M.L., Sahai S., Rucker L., Blanchette J.O. Use of culture geometry to control hypoxia-induced vascular endothelial growth factor secretion from adipose-derived stem cells: optimizing a cell-based approach to drive vascular growth. Tissue. Eng. A 2013, 19:2330-2338.
143. Waschow M.L., Boettcher S., Kelm J. High-content analysis of biomarker intensity and distribution in 3D microtissues. Nat. Methods 2012, 9:i-v.
144. Zhang S., Hosaka M., Yoshihara T., Negishi K., Iida Y., Tobita S., Takeuchi T. Phosphorescent light-emitting iridium complexes serve as a hypoxia-sensing probe for tumor imaging in living animals. Cancer Res. 2010, 70:4490-4498.
145. Yoshii Y., Waki A., Yoshida K., Kakezuka A., Kobayashi M., Namiki H., Kuroda Y., Kiyono Y., Yoshii H., Furukawa T., Asai T., Okazawa H., Gelovani J.G., Fujibayashi Y. The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation. Biomaterials 2011, 32:6052-6058.
146. Steiner M.S., Duerkop A., Wolfbeis O.S. Optical methods for sensing glucose. Chem. Soc. Rev. 2011, 40:4805-4839.
147. Balut C., vandeVen M., Despa S., Lambrichts I., Ameloot M., Steels P., Smets I. Measurement of cytosolic and mitochondrial pH in living cells during reversible metabolic inhibition. Kidney Int. 2008, 73:226-232.
148. Han J., Loudet A., Barhoumi R., Burghardt R.C., Burgess K. A ratiometric pH reporter for imaging protein-dye conjugates in living cells. J. Am. Chem. Soc. 2009, 131:1642-1643.
149. San Martin A., Ceballo S., Ruminot I., Lerchundi R., Frommer W.B., Barros L.F. A genetically encoded FRET lactate sensor and its use to detect the Warburg effect in single cancer cells. PLoS One 2013, 8:e57712.
150. Hirata E., Yukinaga H., Kamioka Y., Arakawa Y., Miyamoto S., Okada T., Sahai E., Matsuda M. In vivo fluorescence resonance energy transfer imaging reveals differential activation of Rho-family GTPases in glioblastoma cell invasion. J. Cell Sci. 2012, 125:858-868.
151. Keithley R.B., Weaver E.M., Metzinger M.P., Rosado A.M., Hummon A.B., Dovichi N.J. Single cell metabolic profiling of tumor mimics. Anal. Chem. 2013, 85:8910-8918.
152. Schlabach M.R., Luo J., Solimini N.L., Hu G., Xu Q., Li M.Z., Zhao Z., Smogorzewska A., Sowa M.E., Ang X.L., Westbrook T.F., Liang A.C., Chang K., Hackett J.A., Harper J.W., Hannon G.J., Elledge S.J. Cancer proliferation gene discovery through functional genomics. Science 2008, 319:620-624.
153. Li X., Zhang X., Zhao S., Wang J., Liu G., Du Y. Micro-scaffold array chip for upgrading cell-based high-throughput drug testing to 3D using benchtop equipment. Lab Chip 2014, 14:471-481.
154. Hoover E.E., Squier J.A. Advances in multiphoton microscopy technology. Nat. Photonics 2013, 7.